Viridian Therapeutics, Inc. (VRDN)

NASDAQ

$33.03

+$0.72 (2.23%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$32.76$34.04

Open $33.67

52 Week Range

$9.90$34.02

Previous Close $32.31

Market Cap2.68B

Volume2.18M

Avg Volume1.42M

P/E (TTM)-7.83

EPS (TTM)$-4.22

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Viridian Therapeutics, Inc.

DEC52025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: Business Wire•10 days ago

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the C...

NOV72025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: Business Wire•38 days ago

NOV52025

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Source: Business Wire•40 days ago

NOV32025

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Source: Business Wire•42 days ago

OCT212025

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Source: Business Wire•55 days ago

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced the pricing o...

OCT212025

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Source: Business Wire•55 days ago

OCT202025

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Source: Business Wire•56 days ago

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered ...

OCT22025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: Business Wire•74 days ago

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the...